Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 77.29 Million USD | -48.09% |
| 2022 | 148.9 Million USD | -27.15% |
| 2021 | 204.38 Million CAD | -44.46% |
| 2020 | 367.97 Million CAD | -5.91% |
| 2019 | 391.08 Million CAD | 49.21% |
| 2018 | 262.1 Million CAD | 157.96% |
| 2017 | 101.6 Million CAD | 120.98% |
| 2016 | 45.98 Million CAD | 107.56% |
| 2015 | 22.15 Million CAD | 1895.64% |
| 2014 | 1.11 Million CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 61.75 Million USD | 9.35% |
| 2023 Q4 | 57.05 Million USD | -34.35% |
| 2023 Q3 | 86.91 Million USD | -0.63% |
| 2023 Q2 | 87.47 Million USD | -38.43% |
| 2023 Q1 | 142.06 Million USD | -4.59% |
| 2023 FY | 77.29 Million USD | -48.09% |
| 2022 Q1 | 205.51 Million CAD | 0.55% |
| 2022 FY | 148.9 Million USD | -27.15% |
| 2022 Q4 | 148.9 Million USD | -30.4% |
| 2022 Q3 | 213.93 Million CAD | 1.29% |
| 2022 Q2 | 211.2 Million CAD | 2.77% |
| 2021 Q3 | 365.75 Million CAD | 3.52% |
| 2021 Q2 | 353.3 Million CAD | -14.18% |
| 2021 Q4 | 204.38 Million CAD | -44.12% |
| 2021 Q1 | 411.67 Million CAD | 11.87% |
| 2021 FY | 204.38 Million CAD | -44.46% |
| 2020 Q3 | 394.02 Million CAD | -1.11% |
| 2020 Q1 | 389.8 Million CAD | -0.33% |
| 2020 Q2 | 398.45 Million CAD | 2.22% |
| 2020 FY | 367.97 Million CAD | -5.91% |
| 2020 Q4 | 367.97 Million CAD | -6.61% |
| 2019 Q4 | 391.08 Million CAD | -37.18% |
| 2019 Q3 | 622.57 Million CAD | 34.83% |
| 2019 Q1 | 393.73 Million CAD | 50.22% |
| 2019 FY | 391.08 Million CAD | 49.21% |
| 2019 Q2 | 461.75 Million CAD | 17.28% |
| 2018 FY | 262.1 Million CAD | 157.96% |
| 2018 Q4 | 262.1 Million CAD | 41.71% |
| 2018 Q2 | 150.4 Million CAD | 27.24% |
| 2018 Q3 | 184.96 Million CAD | 22.97% |
| 2018 Q1 | 118.2 Million CAD | 16.33% |
| 2017 Q2 | 73.76 Million CAD | 12.64% |
| 2017 Q4 | 101.6 Million CAD | 8.97% |
| 2017 FY | 101.6 Million CAD | 120.98% |
| 2017 Q1 | 65.48 Million CAD | 42.42% |
| 2017 Q3 | 93.24 Million CAD | 26.4% |
| 2016 Q2 | 27.57 Million CAD | 13.79% |
| 2016 FY | 45.98 Million CAD | 107.56% |
| 2016 Q4 | 45.98 Million CAD | -9.12% |
| 2016 Q3 | 50.59 Million CAD | 83.47% |
| 2016 Q1 | 24.23 Million CAD | 9.41% |
| 2015 Q4 | 22.15 Million CAD | -2.87% |
| 2015 Q2 | 14.1 Million CAD | 86.32% |
| 2015 FY | 22.15 Million CAD | 1895.64% |
| 2015 Q1 | 7.57 Million CAD | 18.62% |
| 2015 Q3 | 22.8 Million CAD | 61.68% |
| 2014 Q1 | 1.2 Million CAD | 1679.94% |
| 2014 Q3 | 1.11 Million CAD | 70.12% |
| 2014 Q2 | 652.51 Thousand CAD | -45.73% |
| 2014 Q4 | 6.38 Million CAD | 475.01% |
| 2014 FY | 1.11 Million CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q4 | 67.55 Thousand CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Theratechnologies Inc. | 6.06 Million USD | -1174.184% |
| Harrow Health, Inc. | 10.86 Million USD | -611.254% |
| Dynavax Technologies Corporation | 53.29 Million USD | -45.04% |
| Biofrontera Inc. | 10.9 Million USD | -608.581% |
| Cronos Group Inc. | 30.33 Million USD | -154.761% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -2742.663% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -7729199900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -1256.23% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -1576.848% |
| Radius Health, Inc. | 278.64 Million USD | 72.261% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -2211.871% |
| DURECT Corporation | 2.21 Million USD | -3383.191% |
| ProPhase Labs, Inc. | 3.84 Million USD | -1912.288% |
| Safety Shot Inc | 1.86 Million USD | -4034.042% |
| Phibro Animal Health Corporation | 265.91 Million USD | 70.933% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -9445.086% |
| Alvotech | 74.43 Million USD | -3.841% |
| Assertio Holdings, Inc. | 37.68 Million USD | -105.095% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 0.15% |
| Rockwell Medical, Inc. | 5.87 Million USD | -1216.505% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1247.782% |
| Procaps Group S.A. | 96.83 Million USD | 20.18% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -563.622% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -511.826% |
| Viatris Inc. | 3.46 Billion USD | 97.772% |
| OptiNose, Inc. | 8.05 Million USD | -859.911% |
| SIGA Technologies, Inc. | 64.21 Million USD | -20.358% |
| Tilray Brands, Inc. | 252.08 Million USD | 69.339% |
| PetIQ, Inc. | 159.3 Million USD | 51.483% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1247.782% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -101.807% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -2787.141% |
| Alimera Sciences, Inc. | 1.87 Million USD | -4013.465% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -139.057% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -173.571% |
| Journey Medical Corporation | 10.2 Million USD | -657.319% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -4699.58% |
| Alpha Teknova, Inc. | 11.59 Million USD | -566.655% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -1624.113% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | -93.331% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 4.78 Million USD | -1513.93% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -644.624% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 49.183% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 50691.054% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 25.932% |
| Incannex Healthcare Limited | -10.01 Million USD | 871.762% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -30287.809% |
| Shineco, Inc. | 1.58 Million USD | -4765.646% |
| Procaps Group, S.A. | 96.83 Million USD | 20.18% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 30.49% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -1041.853% |
| Lantheus Holdings, Inc. | 64.02 Million USD | -20.714% |
| Alvotech | 74.43 Million USD | -3.841% |
| Hempacco Co., Inc. | 2.54 Million USD | -2939.847% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | -61.719% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -17.782% |
| Kamada Ltd. | 87.74 Million USD | 11.915% |
| Indivior PLC | 141.79 Million USD | 45.492% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -15941.009% |
| Flora Growth Corp. | 8.5 Million USD | -808.463% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -30287.809% |
| Evolus, Inc. | 10.99 Million USD | -602.782% |
| HUTCHMED (China) Limited | 50.25 Million USD | -53.79% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 26.968% |
| Akanda Corp. | 1.28 Million USD | -5906.089% |